Streetbeat News

Earnings

DE

Deere & Co (NYSE:DE) reported Q3 earnings that beat expectations despite a 17% decline in net sales and revenue. The company reaffirmed its 2024 net income outlook. DE shares traded higher by 1.15% premarket.

Portfolio Pulse from Akanksha Bakshi

August 15, 2024 | 12:23 pm

TPR

Tapestry shares are trading higher after the company reported better-than-expected Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:21 pm

SLNH

Soluna Holdings reported Q2 revenue of $9.7 million, a significant increase from $2.1 million year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:21 pm

CNSP

CNS Pharmaceuticals reported a reduced net loss of $2.5M for Q2 2024, attributed to lower CRO expenses. R&D costs decreased to $1.1M, while G&A expenses increased to $1.4M due to higher legal and professional fees. The company has a cash position of $1.5M, with an additional $12.4M raised post-June 30, ensuring sufficient funds through Q1 2025. Final Berubicin trial data is expected in H1 2025.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:18 pm

CLBT

Cellebrite shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates. Additionally, the company issued Q3 revenue guidance above estimates.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:17 pm

LITE

Lumentum Holdings shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 revenue guidance above estimates. Additionally, Rosenblatt and Needham raised their respective price targets on the stock.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:15 pm

AISP

CING

WMT

On August 15th, Walmart (WMT) raised its FY25 adjusted EPS outlook, Cingulate (CING) received a European patent for its lead asset CTx-1301, and Airship AI Holdings (AISP) reported a year-over-year increase in Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:14 pm

PRFX

PainReform reported R&D expenses of $11.4M for H1 2024 due to a Phase 3 trial, resulting in a net loss of $12.8M. G&A expenses decreased to $1.5M, and the cash position is at $2.8M following a $4M public offering in April.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:14 pm

ARQT

EBS

EH

GGR

NHI

PGEN

SNOW

TITN

Titan Machinery, Precigen, Gogoro, and other major stocks experienced significant declines in Thursday's pre-market session. Titan Machinery reported weak preliminary Q2 results, leading to a 26.9% drop in its share price. Precigen, Gogoro, Snowflake, National Health Investors, Arcutis Biotherapeutics, EHang Holdings, and Emergent BioSolutions also saw notable declines.

Portfolio Pulse from Avi Kapoor

August 15, 2024 | 12:11 pm

CVM

CEL-SCI (AMEX:CVM) reported a Q3 2024 adjusted EPS of $(0.14), missing the analyst consensus estimate of $(0.11) by 27.27%.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:04 pm